|
ATE199392T1
(de)
|
1992-12-04 |
2001-03-15 |
Medical Res Council |
Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
|
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
DE69829891T2
(de)
|
1997-04-07 |
2005-10-06 |
Genentech, Inc., South San Francisco |
Anti-VEGF Antikörper
|
|
US7112661B1
(en)
|
1998-10-30 |
2006-09-26 |
The Research Foundation Of State University Of New York |
Variable heavy chain and variable light chain regions of antibodies to human platelet glycoprotein Ib alpha
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
IT1320715B1
(it)
|
2000-10-19 |
2003-12-10 |
Cselt Centro Studi Lab Telecom |
Modulo generatore di circuiti per la decodifica di codiciconvoluzionali, metodo per la generazione di tale tipo di circuito e
|
|
EP1355919B1
(en)
|
2000-12-12 |
2010-11-24 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
AU2002368077B2
(en)
|
2001-07-12 |
2010-03-04 |
Jefferson Foote |
Super humanized antibodies
|
|
EP1411851B1
(en)
|
2001-08-03 |
2006-11-02 |
Tyco Healthcare Group LP |
Marker for use with a tissue marking apparatus
|
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
US20060235208A1
(en)
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
EP2551282A3
(en)
|
2005-03-23 |
2013-02-13 |
Genmab A/S |
Antibodies against CD38 for treatment of multiple myeloma
|
|
TW200745162A
(en)
|
2005-05-24 |
2007-12-16 |
Morphosys Ag |
Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
|
|
DK1931709T3
(en)
|
2005-10-03 |
2017-03-13 |
Xencor Inc |
FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
|
|
CN101287764B
(zh)
|
2005-10-12 |
2013-11-13 |
莫佛塞斯公司 |
特异性针对人CD38的完全人HuCAL GOLD-衍生治疗抗体的生成和鉴定
|
|
EP2975057A1
(en)
|
2006-07-10 |
2016-01-20 |
Fujita Health University |
Novel anti-cd73 antibody
|
|
PL2081595T3
(pl)
|
2006-09-26 |
2019-11-29 |
Genmab As |
Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
US20090076249A1
(en)
|
2007-09-19 |
2009-03-19 |
Michel De Weers |
Antibodies against CD38 for treatment of multiple myeloma
|
|
JP5737944B2
(ja)
|
2007-12-17 |
2015-06-17 |
ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ |
間質性膀胱炎の治療
|
|
KR20110028450A
(ko)
|
2008-06-16 |
2011-03-18 |
이뮤노젠 아이엔씨 |
새로운 상승 효과
|
|
EP2328615A2
(en)
|
2008-08-20 |
2011-06-08 |
Centocor Ortho Biotech Inc. |
Engineered anti-il-13 antibodies, compositions, methods and uses
|
|
EP2191840A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
|
|
EP2191842A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine
|
|
EP2191843A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
|
|
EP2191841A1
(en)
|
2008-11-28 |
2010-06-02 |
Sanofi-Aventis |
Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine
|
|
EP2580243B1
(en)
|
2010-06-09 |
2019-10-16 |
Genmab A/S |
Antibodies against human cd38
|
|
US8877899B2
(en)
|
2010-09-27 |
2014-11-04 |
Morphosys Ag |
Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL
|
|
UA112170C2
(uk)
|
2010-12-10 |
2016-08-10 |
Санофі |
Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
|
|
GB2486424A
(en)
|
2010-12-13 |
2012-06-20 |
Univ Sussex |
Markers for plasma cell disorders
|
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
|
RU2013140975A
(ru)
|
2011-02-28 |
2015-04-10 |
Дженентек, Инк. |
Биологические маркеры и способы прогнозирования восприимчивости к антагонистам в-клеток
|
|
AU2012250924B2
(en)
|
2011-05-02 |
2017-05-25 |
Immunomedics, Inc. |
Ultrafiltration concentration of allotype selected antibodies for small-volume administration
|
|
GB201203938D0
(en)
|
2012-03-06 |
2012-04-18 |
Binding Site Group The Ltd |
Assay system
|
|
GB201212900D0
(en)
|
2012-07-20 |
2012-09-05 |
Binding Site Group The Ltd |
Triage scoring system
|
|
US10342869B2
(en)
|
2012-12-07 |
2019-07-09 |
The Regents Of The University Of California |
Compositions comprising anti-CD38 antibodies and lenalidomide
|
|
UA118255C2
(uk)
|
2012-12-07 |
2018-12-26 |
Санофі |
Композиція, яка містить антитіло до cd38 і леналідомід
|
|
US20160075766A1
(en)
|
2013-05-21 |
2016-03-17 |
Roche Diagnostics Operations, Inc. |
Method for producing antibodies using ovine b-cells and uses thereof
|
|
EP3009518B1
(en)
|
2013-06-11 |
2020-08-12 |
National Center of Neurology and Psychiatry |
Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (rrms) patient, and method for determining applicability of novel therapy
|
|
SG11201600666SA
(en)
|
2013-07-30 |
2016-02-26 |
Sbi Biotech Co Ltd |
Medicament comprising anti-phospholipase d4 antibody
|
|
MX373301B
(es)
|
2013-10-31 |
2020-04-24 |
Sanofi Sa |
Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
|
|
UA119352C2
(uk)
|
2014-05-01 |
2019-06-10 |
Тева Фармасьютикалз Острейліа Пті Лтд |
Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
|
|
US10617757B2
(en)
|
2014-08-08 |
2020-04-14 |
The Regents Of The University Of California |
Methods for treating multiple myeloma
|
|
WO2016040294A2
(en)
|
2014-09-09 |
2016-03-17 |
Janssen Biotech, Inc. |
Combination therapies with anti-cd38 antibodies
|
|
MA41555A
(fr)
|
2015-02-17 |
2017-12-26 |
Millennium Pharm Inc |
Polythérapie pour le traitement du cancer
|
|
US10533057B2
(en)
|
2015-05-13 |
2020-01-14 |
Morphosys Ag |
Treatment for multiple myeloma (MM)
|
|
CR20170526A
(es)
|
2015-05-20 |
2018-04-03 |
Janssen Biotech Inc |
ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
|
|
JP7027321B2
(ja)
|
2015-11-03 |
2022-03-01 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｃｄ３８抗体の皮下製剤及びその使用
|
|
US20170121417A1
(en)
*
|
2015-11-03 |
2017-05-04 |
Janssen Biotech, Inc. |
Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses
|
|
MA45674A
(fr)
|
2016-07-15 |
2019-05-22 |
Takeda Pharmaceuticals Co |
Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
|
|
US20180117150A1
(en)
|
2016-11-01 |
2018-05-03 |
Janssen Biotech, Inc. |
Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide
|
|
US11618787B2
(en)
|
2017-10-31 |
2023-04-04 |
Janssen Biotech, Inc. |
Methods of treating high risk multiple myeloma
|
|
MX2020007429A
(es)
|
2018-01-12 |
2020-10-15 |
Takeda Pharmaceuticals Co |
Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
|
|
CN120501855A
(zh)
|
2019-05-14 |
2025-08-19 |
赛诺菲-安万特美国有限责任公司 |
给予抗cd38抗体以治疗多发性骨髓瘤的方法
|